Compare MRVI & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRVI | WVE |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 994.1M |
| IPO Year | 2020 | 2015 |
| Metric | MRVI | WVE |
|---|---|---|
| Price | $5.76 | $5.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 16 |
| Target Price | $4.13 | ★ $29.81 |
| AVG Volume (30 Days) | 2.0M | ★ 2.9M |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.29 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $185,743,000.00 | $3,704,000.00 |
| Revenue This Year | $12.54 | N/A |
| Revenue Next Year | $7.87 | $85.67 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 149.43 |
| 52 Week Low | $2.29 | $5.01 |
| 52 Week High | $7.44 | $21.73 |
| Indicator | MRVI | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 36.84 | 40.53 |
| Support Level | $5.54 | N/A |
| Resistance Level | $6.55 | $6.39 |
| Average True Range (ATR) | 0.31 | 0.36 |
| MACD | -0.12 | -0.06 |
| Stochastic Oscillator | 25.37 | 15.36 |
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.
WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.